IRIS
STELLA, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.038
AS - Asia 1.391
EU - Europa 1.298
SA - Sud America 345
AF - Africa 280
OC - Oceania 1
Totale 6.353
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.957
SG - Singapore 634
IT - Italia 628
CN - Cina 402
BR - Brasile 317
IE - Irlanda 219
CI - Costa d'Avorio 184
IN - India 108
VN - Vietnam 87
UA - Ucraina 81
DE - Germania 80
CA - Canada 58
SN - Senegal 58
RU - Federazione Russa 45
GB - Regno Unito 44
KR - Corea 44
FI - Finlandia 36
SE - Svezia 28
BE - Belgio 22
PL - Polonia 22
JP - Giappone 17
AR - Argentina 16
FR - Francia 16
ES - Italia 15
NL - Olanda 15
CZ - Repubblica Ceca 14
MX - Messico 14
TR - Turchia 13
ZA - Sudafrica 13
BD - Bangladesh 11
IQ - Iraq 11
UZ - Uzbekistan 11
HK - Hong Kong 10
ID - Indonesia 9
CH - Svizzera 8
NG - Nigeria 8
IL - Israele 7
IR - Iran 6
MA - Marocco 6
AE - Emirati Arabi Uniti 5
GR - Grecia 5
AT - Austria 4
EC - Ecuador 4
NO - Norvegia 4
TN - Tunisia 4
BJ - Benin 3
DO - Repubblica Dominicana 3
KZ - Kazakistan 3
AZ - Azerbaigian 2
BG - Bulgaria 2
CO - Colombia 2
HU - Ungheria 2
KE - Kenya 2
LB - Libano 2
LT - Lituania 2
PE - Perù 2
PY - Paraguay 2
RS - Serbia 2
SA - Arabia Saudita 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AU - Australia 1
EG - Egitto 1
GD - Grenada 1
GL - Groenlandia 1
HN - Honduras 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
LV - Lettonia 1
MY - Malesia 1
NA - Namibia 1
NP - Nepal 1
PK - Pakistan 1
PS - Palestinian Territory 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UY - Uruguay 1
VE - Venezuela 1
Totale 6.353
Salva come PNG Salva come JPEG
Città #
Santa Clara 517
Dallas 474
Chandler 326
Singapore 325
Chicago 231
Dublin 219
Abidjan 184
Catania 179
Ashburn 144
Jacksonville 96
Beijing 90
Hefei 85
Boardman 84
Kochi 79
Los Angeles 79
Cambridge 60
Lawrence 59
Dakar 57
Andover 55
Civitanova Marche 54
New York 43
Seoul 43
Palermo 38
Grafing 35
Nanjing 34
Des Moines 30
Wilmington 29
Milan 28
São Paulo 27
The Dalles 27
Buffalo 26
Dong Ket 26
Toronto 26
Columbus 25
Brussels 22
Turku 22
Munich 19
Rome 19
Council Bluffs 18
Ho Chi Minh City 18
Hanoi 17
Tokyo 17
Warsaw 16
Bari 15
Brno 13
Messina 13
Montreal 13
San Mateo 13
Santa Venerina 12
Seattle 12
Belo Horizonte 11
Jiaxing 11
Johannesburg 11
Nanchang 11
Ottawa 11
Rio de Janeiro 11
Falls Church 10
Aci Catena 9
Boston 9
Bremen 9
Chennai 9
Lappeenranta 9
Saint Petersburg 9
Abuja 8
Brooklyn 8
Curitiba 8
Hong Kong 8
London 8
Stockholm 8
Amsterdam 7
Brasília 7
Hanover 7
Hebei 7
Pune 7
Redmond 7
San Francisco 7
Tashkent 7
Jakarta 6
Manchester 6
Redondo Beach 6
Scottsdale 6
Atlanta 5
Fairfield 5
Florence 5
Frankfurt am Main 5
Giardini-Naxos 5
Helsinki 5
Manaus 5
Mascalucia 5
Miami 5
Orem 5
Phoenix 5
Querétaro 5
San Giovanni la Punta 5
Shenyang 5
Verona 5
Belém 4
Casablanca 4
Changsha 4
Comiso 4
Totale 4.442
Salva come PNG Salva come JPEG
Nome #
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 179
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 134
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 132
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 130
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 129
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily 128
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer? 127
Biomarkers and prognostic factors for malignant pleural mesothelioma 125
The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias 125
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 122
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 119
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 118
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 118
Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells 114
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 113
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 112
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 110
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 109
A case of high-risk AML in a patient with advanced systemic mastocytosis 108
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 105
Rufloxacin induced photosensitization in bio-models of increasing complexity 104
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 104
Double-face activity of resveratrol in voluntary runners: assessment of DNA damage by comet assay. 99
New insights in thyroid cancer and p53 family proteins 99
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 99
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 97
An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma 97
Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity 96
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 95
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 94
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 92
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 91
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 90
Opportunities and challenges of liquid biopsy in thyroid cancer 89
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 87
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform 87
Uncommon long-term survival in a patient with chronic myeloid leukemia 86
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 86
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer 83
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors 81
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 81
Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma 81
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 80
Approcci Terapeutici Innovativi per il Trattamento di Cellule di Leucemia Mieloide Cronica Resistenti ad Imatinib Mesilato 79
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase 79
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 79
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study 77
Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy 77
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells 77
THE ROLE OF SPARC IN CHRONIC MYELOID LEUKEMIA 76
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 75
Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells 75
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 73
Second-line dasatinib therapy improved compliance and deep molecular responses in imatinib-intolerant chronic myeloid leukemia patients 73
In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients 72
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 71
High BCR-ABL/GUS(IS) Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib 70
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia 70
A Multiplex Assay for Fast PIK3CA Hotspot Mutation Characterization in a Single Specimen by 3-Color Digital PCR Analysis 68
The Role of New Technologies in Myeloproliferative Neoplasms 68
Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51 68
Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment 63
Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer 62
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance 62
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 61
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy 61
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis 58
REThinking the role of the RET oncogene in breast cancer 57
The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities 57
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain 53
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level 51
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes 50
Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer 16
Totale 6.533
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.941
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.941
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021241 0 0 0 0 68 20 27 2 53 3 33 35
2021/2022435 20 67 11 7 78 8 64 15 25 11 30 99
2022/20231.036 68 82 56 119 58 148 13 201 209 14 46 22
2023/2024553 44 83 26 24 19 132 8 33 7 23 112 42
2024/20252.107 30 330 79 152 412 291 166 64 75 143 255 110
2025/20261.764 253 240 584 288 399 0 0 0 0 0 0 0
Totale 6.533